This insightful article explores the use of inhaled Technosphere insulin, a fast-acting insulin administered via inhalation, in managing diabetes. Through three compelling case studies, faculty member Christopher Jacobson, PharmD, and his co-authors illustrate how this innovative approach can significantly improve glycemic control, reduce the risk of hypoglycemia, and enhance the quality of life for people with diabetes. The study highlights the benefits of continuous glucose monitoring (CGM) metrics, such as Time in Range (TIR) and Time above Range (TAR), in providing a comprehensive understanding of glucose management beyond the traditional A1C levels.
You can read the full article here: Inhaled Technosphere Insulin for Individualized Diabetes Management.